SAT0393

EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY

Proton Rahman¹, Regan Arendse², Isabelle Fortin³, Andrew Chow⁴, Majed Khraishi⁵, Suneil Kapur⁶, Michel Zimmer⁷, Jon Chan⁸, Larissa Lisnevskia⁹, Raheem Kherani¹⁰, Emmanouil Rampakakis¹¹, Odalis Asin Milan¹¹, Allen Lehman¹¹, Meagan Rachich¹², Francois Nantel¹¹. ¹Memorial University of Newfoundland, St. John's, Canada; ²University of Saskatchewan, Saskatoon, Canada; ³Centre Rhumatologie de l'Est, Rimouski, Canada; ⁴University of Toronto, Toronto, Canada; ⁵Nexus Clinical Research, St. John's, Canada; ⁶University of Ottawa, Ottawa, Canada; ⁷University of Montreal, Montreal, Canada; ⁸Artus Health Centre, Vancouver, Canada; ⁹Oshawa Clinic, Oshawa, Canada; ¹⁰University of British Columbia, Richmond, Canada; ¹¹Janssen Inc, Toronto, Canada; ¹²Janssen Inc., Toronto, Canada

Background: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time.

Objectives: To describe the profile of psoriatic arthritis (PsA) patients selected for treatment with infliximab (IFX), golimumab (GLM) or ustekinumab (UST) treatment in Canadian routine care and to describe the long-term real-world effectiveness and safety of these agents.

Methods: 462 PsA patients treated with IFX, GLM or UST were enrolled into the Biologic Treatment Registry Across Canada (BioTRAC) registry between 2006-2015, 2010-2017 and 2014-2017, respectively. Study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed with changes in TJC28, SJC28, skin, enthesitis, dactylitis, pain, HAQ, acute phase reactants. Safety was evaluated with the incidence of adverse events (AEs) and drug survival rates.

Results: Of the 111 IFX-, 281 GLM- and 70 UST-treated patients, the proportion of males were 52.3%, 46.3% and 37.1%, the mean age was 48.4, 52.8 and 53.1 years and the mean disease duration was 5.8, 6.1 and 5.7 years, respectively. Most patients were bio-naïve (85.6%, 77.9% and 55.7% for IFX, GLM and UST, respectively ($p < 0.001$). A reduction in mean baseline duration of morning stiffness was observed in the IFX cohort (from 69.8 to 42.6 to 23 min in 2006-2008 to 2009-2012 to 2013-2015; $p = 0.003$). Most other baseline disease parameters remained similar over time in all three cohorts. However, UST-treated patients had lower mean baseline DAS28 CRP (3.4 vs 3.9; $p = 0.0031$), SJC (3.8 vs 5.3; $p = 0.0046$) and higher PASI (4.8 vs 2.2; $p = 0.0061$) compared to patients treated with GLM.

Treatment with IFX, GLM and UST was associated with significant improvements in all disease parameters over time ($P < 0.001$) from baseline up to 84, 84 and 40 months, respectively with similar efficacy between agents. The only exception was the proportion of patients in minimal disease activity at 12, 24 and 36 months which reached 40.7%, 50.0% and 55% in IFX-patients; 64.7%, 68.8% and 78.9% in GLM-patients and 58.8%, 60.0% and 83.3% in UST-patients ($p = 0.004$ and $p < 0.001$ vs IFX).

AEs were reported for 74.8%, 69.8% and 52.9% (138, 114 and 115 events/100 PYs) and SAEs for 19.8%, 8.5% and 5.7% (8.8, 19.6 and 28.6 events/100 PYs) covering 325, 567 and 87 years of exposure for IFX-, GLM- and UST-treated patients, respectively. One, one and no death occurred IFX-, GLM- and UST-treated patients, respectively. The proportion of patients who discontinued treatment were 63.1%, 50.9% and 50.0% over a mean exposure of 2.9, 1.9 and 1.2 years to IFX, GLM and UST, respectively.

Conclusion: Differences in baseline characteristics between patients treated with an anti-TNF over an anti-IL12/23 agent suggest that the level of joint to skin involvement might be driving physician choice when the time comes to choose a biologic agent. IFX, GLM and UST treatment significantly reduced disease activity and improved functionality in a similar fashion and were well tolerated in patients with PsA.

Disclosure of Interests: : Proton Rahman: None declared, Regan Arendse Grant/research support from: Janssen Sponsored Study, Isabelle Fortin Grant/research support from: ABBVIE, AMGEN, ASTRAZENECA, BMS, CELGENE, GSK, JANSSEN, PFIZER, SANOFI, UCB, Consultant for: LILLY, NOVARTIS, SANOFI, Speakers bureau: NOVARTIS, PFIZER, Andrew Chow Grant/research support from: Abbvie, Celgene, Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Consultant for: Abbvie, BMS, Celgene, Eli Lilly, GSK, Janssen, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, Eli Lilly, Janssen, Novartis, Pfizer, Majed Khraishi Grant/research support from: Novartis, Consultant for: Amgen, Celgene, Gebro, Janssen, Novartis, Pfizer, Lilly, Merck, Suneil Kapur Grant/research support from: Abbvie, Merck, Janssen, Novartis, Eli Lilly, Amgen, Michel Zimmer: None declared, Jon Chan Grant/research support from: Janssen, UCB, Novartis, Pfizer, Celgene, Consultant for:

Amgen, Celgene, Eli Lilly, Janssen, Amgen, Abbvie, Novartis, Pfizer, UCB, Sandoz, Merck, Larissa Lisnevskia Grant/research support from: Janssen Sponsored Study, Raheem Kherani Grant/research support from: Janssen, BMS, Abbvie, Consultant for: Abbvie, Amgen, BMS, Janssen, Lilly, Merck, Pfizer, Roche, Speakers bureau: Janssen, BMS, Emmanouil Rampakakis : None declared, Odalis Asin Milan Employee of: Employee of Janssen, Allen Lehman Employee of: Employee of Janssen, Meagan Rachich Shareholder of: Janssen, Employee of: Employee of Janssen, Francois Nantel Shareholder of: Janssen, Employee of: Employee of Janssen

DOI: 10.1136/annrheumdis-2019-eular.1440

SAT0394

POSSIBLE POTENTIAL INTERACTIONS BETWEEN OBESITY, QUALITY OF LIFE, PSYCHOLOGICAL STATUS AND CLINICAL PARAMETERS IN PSORIATIC ARTHRITIS

Kevser Gok¹, Kemal Nas², Erkan Kilic³, Betül Sargin⁴, Sevtap Acer Kasman⁵, Hakan Alkan⁶, Nilay Sahin⁷, Gizem Cengiz⁸, Nihan Cuzdan⁹, İlknur Albayrak Gezer¹⁰, Dilek Keskin¹¹, Cevriye Mülkoğlu¹², Hatice Resorku¹³, İsmihan Sunar¹⁴, Ajda Bal Hasturk¹⁵, Mehmet Tuncay Duruöz⁵, Okan Kucukakkas¹⁶, Ozan Volkan Yurdakul¹⁶, Meltem Alkan Melikoglu¹⁷, Yildirim Aydin¹², Figen Ayhan¹², Hatice Bodur¹⁸, Mustafa Calis⁸, Erhan Capkin¹⁹, Gül Devrimse²⁰, Sami Hizmetli²¹, Ayhan Kamanli², Yasar Keskin¹⁶, Hilal Kocabas²², Ozgur Kutluk²³, Nesrin Şen²⁴, Omer Faruk Sendur²⁵, Ibrahim Tekeoglu²⁶, Murat Toprak²⁷, Sena Tolu¹⁶, Tiraje Tuncer²³. ¹Ankara Numune TraindRes Hospt, Ankara, Turkey; ²Sakarya Univ, Sakarya, Turkey; ³Afyon Hospt, Afyon, Turkey; ⁴Aydin Hospt, Aydin, Turkey; ⁵Marmara Univ, Istanbul, Turkey; ⁶Pamukkale Univ, Denizli, Turkey; ⁷Balikesir Univ, Balikesir, Turkey; ⁸Erciyes Univ, Kayseri, Turkey; ⁹Sanliurfa TraiandRes Hosptl, Sanliurfa, Turkey; ¹⁰Selçuk Univ, Konya, Turkey; ¹¹Kirikkale Univ, Kirikkale, Turkey; ¹²Ankara TraiandRes Hospt, Ankara, Turkey; ¹³Onsekiz Mart Univ, Canakkale, Turkey; ¹⁴Ankara Univ, Ankara, Turkey; ¹⁵Diskapi TraiandRes Hospt, Ankara, Turkey; ¹⁶Bezmialem Univ, Istanbul, Turkey; ¹⁷Atatürk Univ, Erzurum, Turkey; ¹⁸Yildirim Beyazit Univ, Ankara, Turkey; ¹⁹Karadeniz Technical Univ, Trabzon, Turkey; ²⁰Recep Tayyip Erdoğan Univ, Rize, Turkey; ²¹Cumhuriyet Univ, Sivas, Turkey; ²²Necmettin Erbakan Univ, Konya, Turkey; ²³Akdeniz Univ, Antalya, Turkey; ²⁴Kartal Dr. Lütfi Kırdar TraiandRes Hosptl, Istanbul, Turkey; ²⁵Adnan Menderes Univ, Aydin, Turkey; ²⁶SakaryaUnv, Sakarya, Turkey; ²⁷Yuzuncu Yil Univ, Van, Turkey

Background: Psoriatic arthritis (PsA), a chronic rheumatic disease associated with reduced quality of life. Obesity is an important clinical problem which may interfere with loss of functioning and quality of life. Obesity is usually an overlooked entity in patients with PsA. Several studies were investigated prevalence and the impact of obesity on disease activity in patients with PsA, however relationship between psychological status and quality of life have not been evaluated comparatively.

Objectives: To assess the impact of obesity on quality of life, psychological status and clinical parameters in patients with PsA.

Methods: Patients with PsA were recruited who met CASPAR classification criteria enrolled by Turkish League Against Rheumatism-NETWORK (TLAR-NETWORK) derived from 24 different centers of our country. Patients with BMI ≥ 30 kg/m² were considered obese. Differences among patients with or without obesity were assessed. VAS fatigue, psychological status and health related quality of life measures [SF-36; HAQ; Psoriatic arthritis quality of life (PsAQoL); Hospital Anxiety and Depression Scale], FACIT-Fatigue, DAS28, BASDAI, BASFI, BASMI, Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and Psoriasis area severity index (PASI) scores were compared between these groups.

Results: A total 1130 patients with PsA (36.0% male, 64.0% female) included in this study. In this cohort 37.6% obese and 62.4% non-obese. The presence of peripheral arthritis, enthesitis, dactylitis, uveitis and spine involvement, PASI scores as well as MASES scores were quite similar between patients with and without obesity. Obese patients had significantly higher scores in VAS fatigue and disease activity, poorer QoL and physical functions compared to non-obese patients ($p < 0.05$). Obese patients had high risk for anxiety and depression ($p < 0.05$).

Conclusion: Obesity associated with the risk of depression and anxiety, fatigue, poorer QoL and higher disease activity. These findings suggest that obesity should be considered while assessing patients with PsA.

REFERENCES

- Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. *Ann Rheum Dis*. 2012 Aug; 71(8):1267-72.
- Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. *Arthritis Res Ther*. 2019 Jan 11; 21(1):17